Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of protein tyrosine phosphatase SHP2 inhibitor in preparation of medicine for treating psoriasis

A technology of tyrosine phosphatase and inhibitor is applied in the application field of preparing medicines for treating psoriasis, and can solve problems such as unreported

Active Publication Date: 2020-06-12
NANJING UNIV
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There has been no report about its unique pharmacological effects in the treatment of immune diseases, especially in the treatment of psoriasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of protein tyrosine phosphatase SHP2 inhibitor in preparation of medicine for treating psoriasis
  • Application of protein tyrosine phosphatase SHP2 inhibitor in preparation of medicine for treating psoriasis
  • Application of protein tyrosine phosphatase SHP2 inhibitor in preparation of medicine for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1. Pharmacological experiment of SHP099: imiquimod-induced mouse psoriasis model [1]

[0022] C57BL / 6 female mice, aged 6-8 weeks, weighing 18-22 grams, were raised in an SPF animal room at 21±2°C, free to drink and eat, and alternate day and night for 12 hours. After the mouse was anesthetized with 1% pentobarbital sodium, the hair on the back of the mouse was shaved in an area of ​​about 2 cm×2 cm to expose the back skin. Two days later, the mice were randomly divided into 6 groups, normal group (Sham group), model group (Imiquimod, IMQ group), positive control group (Secukinumab group) 10mg / kg, SHP099 low, middle and high dose groups (1mg / kg). kg, 3mg / kg, 10mg / kg). In recent years, more and more studies have proved that the "IL-23 / Th17 cell axis" plays a vital role in the pathogenesis of psoriasis. Among them, IL-17A is highly expressed in psoriasis-affected skin, and drugs targeting this target have also shown excellent effects. The positive control drug Secukin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of pharmacy. According to the application of a protein tyrosine phosphatase SHP2 inhibitor SHP099 in preparation of the medicine for treating psoriasis, aiming at an imiquimod-induced mouse psoriasis-like disease model, the SHP099 can effectively improve epidermal thickening of mouse skin lesion tissues, inflammatory cell infiltration and the level of inflammatory factors in mouse serum. At the cellular level, the SHP099 can significantly reduce the release of inflammatory factors related to psoriasis.

Description

technical field [0001] The present invention relates to a new application of SHP099, an inhibitor of protein tyrosine phosphatase SHP2, in particular to the application of SHP099 in the preparation of medicines for treating psoriasis. Background technique [0002] SHP099 was developed as an allosteric inhibitor of the protein tyrosine phosphatase SHP2 in 2016, and the research on this compound mainly focuses on antitumor aspects. So far, there is no report about its unique pharmacological effect in treating immune diseases, especially in treating psoriasis. The present invention mainly finds that SHP099 has a significant improvement effect on the mouse psoriasis-like model. [0003] The structural formula of SHP099 is as follows: [0004] Contents of the invention [0005] Purpose of the invention: [0006] The present invention provides a new application of SHP2 inhibitor SHP099. [0007] Technical solutions: [0008] Application of protein tyrosine phosphatase SH...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/497A61P17/06
CPCA61K31/497A61P17/06
Inventor 孙洋徐强朱雨雨郭文洁
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com